Strategies could seek to reduce neutralization by pre-existing antibodies, improve virus binding to JAM-A deficient cancers, optimize the stability-instability balance towards tumor microenvironments, express tumor antigens or cytokines that promote tumor immune responses, or promote bystander tumor cell killing. The gene discussed is F11R; the disease is neoplasm.